Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

Author affiliations

Abstract

We report supramolecular repurposing of emtricitabine (FTC, trade name: Emtriva®), a blockbuster FDA-approved anti-HIV agent. FTC is revealed to act as a hydrogen-bonded cleft for bipyridine recognition. The supramolecular repurposing is realized by the generation of four cocrystals through liquid-assisted grinding. The clefts comprise discrete three-component assemblies sustained by a combination of hydrogen bonds and π⋯π interactions.

Graphical abstract: Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

Back to tab navigation

Supplementary files

Article information


Submitted
28 Mar 2020
Accepted
06 May 2020
First published
06 May 2020

CrystEngComm, 2020, Advance Article
Article type
Communication

Repurposing of the anti-HIV drug emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

G. Campillo-Alvarado, E. A. Keene, D. C. Swenson and L. R. MacGillivray, CrystEngComm, 2020, Advance Article , DOI: 10.1039/D0CE00474J

Social activity

Search articles by author

Spotlight

Advertisements